Pharmacoeconomic review report: Naltrexone hydrochloride and bupropion hydrochloride (Contrave) (Bausch Health, Canada iInc.) :indication: an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., controlled hypertension, type 2 diabetes mellitus, or dyslipidemia)

Naltrexone and bupropion (NB; Contrave) is a fixed-dose combination oral tablet indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults who are obese (body mass index [BMI]: ≥ 30 mg/kg2); or overweight (BMI: ≥ 27 mg/kg2) with the pres...

Full description

Bibliographic Details

Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2020, July 2020
Edition:	Version: Final
Series:	CADTH common drug review
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK565298
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa